SE9502927D0 - Solution containing IGF-I - Google Patents
Solution containing IGF-IInfo
- Publication number
- SE9502927D0 SE9502927D0 SE9502927A SE9502927A SE9502927D0 SE 9502927 D0 SE9502927 D0 SE 9502927D0 SE 9502927 A SE9502927 A SE 9502927A SE 9502927 A SE9502927 A SE 9502927A SE 9502927 D0 SE9502927 D0 SE 9502927D0
- Authority
- SE
- Sweden
- Prior art keywords
- solution containing
- solution
- containing igf
- igf
- stable
- Prior art date
Links
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a stable solution containing Insulin-like Growth Factor I (IGF-I) or any functional analogue thereof as active agent and mannitol in a pH adjusted solution, optionally with a preservative. There should be no sodium chloride. This solution is physically stable without giving any precipitates, it is isotonic and suitable for injection.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9502927A SE9502927D0 (en) | 1995-08-24 | 1995-08-24 | Solution containing IGF-I |
PCT/SE1996/001041 WO1997007816A1 (en) | 1995-08-24 | 1996-08-22 | Solution containing igf-i |
AU68415/96A AU6841596A (en) | 1995-08-24 | 1996-08-22 | Solution containing igf-i |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9502927A SE9502927D0 (en) | 1995-08-24 | 1995-08-24 | Solution containing IGF-I |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9502927D0 true SE9502927D0 (en) | 1995-08-24 |
Family
ID=20399261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9502927A SE9502927D0 (en) | 1995-08-24 | 1995-08-24 | Solution containing IGF-I |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6841596A (en) |
SE (1) | SE9502927D0 (en) |
WO (1) | WO1997007816A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
DE60038118T2 (en) * | 1999-07-12 | 2009-03-05 | Sandoz Ag | FORMULATIONS OF GROWTH HORMONES |
CN112566652A (en) | 2018-06-25 | 2021-03-26 | Jcr制药股份有限公司 | Aqueous liquid preparation containing protein |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
CA2337745C (en) * | 1992-07-31 | 2005-04-12 | Genentech, Inc. | Human growth hormone aqueous formulation |
SE9300105D0 (en) * | 1993-01-15 | 1993-01-15 | Kabi Pharmacia Ab | STABLE PROTEIN SOLUTION |
-
1995
- 1995-08-24 SE SE9502927A patent/SE9502927D0/en unknown
-
1996
- 1996-08-22 AU AU68415/96A patent/AU6841596A/en not_active Abandoned
- 1996-08-22 WO PCT/SE1996/001041 patent/WO1997007816A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1997007816A1 (en) | 1997-03-06 |
AU6841596A (en) | 1997-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2148568T3 (en) | STABLE AQUEOUS SOLUTIONS FORMULATIONS OF ALPHA INTERFERON. | |
ATE197895T1 (en) | AGENTS FOR ARTIFICIAL BROWNING WITH IMPROVED COLOR DEVELOPMENT | |
DE69924232D1 (en) | STABILIZED INSULIN PREPARATIONS | |
MY125556A (en) | Aqueous formulations of peptide | |
DK0493480T3 (en) | Dehydrodidemnin B | |
MX9705954A (en) | Formulations and methods for reducing skin irritation. | |
TR200103149T2 (en) | Methods for protection of virus and mycoplasma | |
EP1329461B8 (en) | Method of eliminating human serum albumin polymers | |
SE9502927D0 (en) | Solution containing IGF-I | |
DE69007546T2 (en) | Hair treatment composition. | |
DK0523406T3 (en) | Use of low pH tri (n-butyl) phosphate in solutions of biologically active proteins for enhanced virucidal action | |
MX9605280A (en) | Stabilization of non-halogenates 3-isothiazolones in aggressive systems. | |
RS49520B (en) | Antimicrobially active mixtures | |
DE69602208D1 (en) | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING DOBUTAMINE | |
UA43797A (en) | Injection form of the preparation, which manifests the anti-ischemic activity | |
MX9710291A (en) | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor. | |
NO930711D0 (en) | AMINO ACID DERIVATIVES CIRCULATED AT THE C-TERMINAL END | |
SU1536770A1 (en) | CHLORIDE BENZYLHEXAMETHYLENETHRAMMONIUM, HAS BACTERICIDAL ACTIVITY IN RESPECT OF SULFATER RESTORING BACTERIA AND PSEUDOMONAS CULTURES | |
ITFE930013U1 (en) | MECHANIZED ORIENTAL STICKS. | |
IT1253704B (en) | Stable therapeutic solutions for injectable use |